Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris

Refractory Angina Pectoris Clinical Trial

Official title:

Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00662727
• Other study ID #: ESMR-RCT-IL
• Status: Completed
• Phase: Phase 2
• First received: April 14, 2008
• Last updated: February 17, 2013
• Start date: January 2007
• Est. completion date: November 2012

Study information

• Verified date: February 2013
• Source: Medispec
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones.

The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.

Description:

Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to myocardial ischemic tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave to avoid arrhythmias. The treatment is painless.

At first, the patient undergoes stress- SPECT testing to identify the ischemic areas. Following that, the same area is localized by the ultra-sound device and the shockwaves are focused to the ischemic area. Several treatments are required for optimal results.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: November 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with chronic stable angina pectoris.

• Documented myocardial segments with reversible ischemia

• AP CCS class of III-IV.

• Stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment.

• Exercise tolerance time < 10 min (modified Bruce)

• Two ETT tests results (within two weeks) averaging no more than 25% of their mean

• Documented epicardial coronary artery disease not amenable to angioplasty or CABG.

• Signed an IRB approved informed consent form.

• Life expectancy of >12 months.

Exclusion Criteria:

• Intraventricular thrombus

• Malignancy in the area of treatment

• Severe COPD

• No smoking during the study procedure

• MI less <3 months prior to treatment

• Severe Valvular disease

• Child bearing potential

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Angina Pectoris
• Refractory Angina Pectoris

Intervention

Device:
• Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Energy Density - 0.09 mJ/mm2
• Placebo
Placebo

Locations

Country	Name	City	State
Israel	Hadassah-Hebrew University Medical Center	Jerusalem

Sponsors (2)

Lead Sponsor	Collaborator
Medispec	Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Exercise Time		6 months	No
Secondary	Change in SPECT		6 months	No
Secondary	Change in AP-CCS		6 months	No